IGBA Statement as new member of the Coalition for Access to NCD Medicines and Products.
The International Generic and Biosimilar medicines Association (IGBA) remains committed to its vision of working to improve patient access to safe, effective, cost-effective, and quality-assured generic and biosimilar medicines.
The 3rd Bioequivalence Conference, co-hosted by the International Generic and Biosimilar Medicines Association (IGBA) and Medicines for Europe, concluded today at the Hilton Amsterdam Airport Schiphol Hotel, The Netherlands. This landmark event brought together experts from regulatory authorities, industry, and academia to discuss the evolving bioequivalence landscape and its critical role in improving global access to medicines.
- IGBA releases first global Intellectual Property and Competition Report (February 2025)
- Joint Industry Statement for WHO's Executive Board Meeting 156 (February 2025)
- IGBA welcomes new chair and new full member (January 2025)
- Lucas Sigman and Allan Oberman appointed 2025 Chair and Vice-Chair of the IGBA CEO Advisory Committee (December 2024)
